DOPASI Foundation is a Pakistan-based non-profit public health and development organisation working across infectious diseases, primary health care, community systems strengthening, digital health, health security, climate and health, and support for vulnerable populations. Its work focuses on integrated, people-centred service delivery, particularly for communities that face barriers to accessing formal health services.
In relation to hepatitis, DOPASI delivers integrated service models for key and underserved populations, including coal miners, brick kiln workers, transgender persons, prisoners, urban poor communities, and other hard-to-reach groups. Hepatitis C screening and referral services are provided alongside TB, HIV, malaria, respiratory health, and other essential health interventions, enabling communities to access multiple services through a single point of contact.
DOPASI’s hepatitis-related activities include community-based Hepatitis C screening and referral, awareness raising and community engagement, demand generation for testing and treatment services, community-led monitoring and accountability mechanisms, and support for linkage to care. The organisation also works closely with government health departments, disease control programmes, community-based organisations, and development partners to strengthen integrated service delivery models and improve access to Hepatitis C and other communicable disease services.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close